Regulatory
Regeneron Pharmaceuticals faces a consolidated securities fraud class action in the U.S. District Court for the Southern District of New York (Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026) filed on behalf of investors who purchased…
Impact: Regeneron is the sole defendant company in the securities class action, accused of misleading investors about the Phase III Fianlimab-Libtayo study. The failed trial and the resulting litigation have erased roughly $11 billion in market capitalization and continue to weigh on investor confidence and management credibility.
Jul 16, 2026 · 240 articles